Picture Berlin Partner Bionnale 2021 Digital Event 650x80px
Document › Details

Vivoryon Therapeutics AG. (10/8/19). "Press Release: Vivoryon Therapeutics AG Launches Rights Offering to Fund its Phase 2b Clinical Development Program in Alzheimer’s Disease with Strong Commitments [Not for US, et al.]". Halle (Saale).

Organisations Organisation Vivoryon Therapeutics AG (Euronext Amsterdam: VVY)
  Group Vivoryon (Group)
  Organisation 2 Den Danske Forskningsfond
  Group CCBR (Group)
Products Product PQ912 (Probiodrug)
  Product 2 phase 2 study
Index terms Index term Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys
  Index term 2 Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG
Persons Person Dauer, Ulrich (Probiodrug 201805– CEO before Omeicos + Activaero + 4SC + Tripos)
  Person 2 Christiansen, Claus (CCBR + Nordic Bioscience Founder + Chairman)

Record changed: 2019-10-17


Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

More documents for Vivoryon (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top